Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R)-5-[(2-carboxyphenyl)carbamoyl]cyclohexa-3,5-diene-1,3-dicarboxylate
(1R)-5-[(3-nitrophenyl)carbamoyl]cyclohexa-3,5-diene-1,3-dicarboxylate
(1R)-5-[(4-nitrophenyl)carbamoyl]cyclohexa-3,5-diene-1,3-dicarboxylate
(2R,3aR)-5-[(methylsulfonyl)methyl]-2,3,3a,4-tetrahydro-1H-indole-2-carboxylate
(2R,5R)-2,3,4,5-tetrahydropyridine-2,5-dicarboxylate
(2R,5R)-5-nitro-2,3,4,5-tetrahydropyridine-2-carboxylate
(2R,7aR)-2,3,7,7a-tetrahydro-1H-indole-2,6-dicarboxylate
(2R,7aR)-6-hydroxy-2,3,7,7a-tetrahydro-1H-indole-2-carboxylate
(2R,7aR)-6-nitro-2,3,7,7a-tetrahydro-1H-indole-2-carboxylate
(2R,8aR)-2,7-dinitro-1,2,8,8a-tetrahydronaphthalene
(3aR)-2-oxo-2,3,3a,4-tetrahydro-1H-benzimidazole-5-carboxylic acid
(3aR)-5-nitro-1,3,3a,4-tetrahydro-2H-benzimidazol-2-one
(3aR)-5-nitro-3a,4-dihydro-1H-indene-1,3(2H)-dione
(3aR)-5-nitro-3a,4-dihydro-1H-isoindole-1,3(2H)-dione
(3aR)-6-chloro-5-nitro-3a,4-dihydro-1H-isoindole-1,3(2H)-dione
(7aR)-2-oxo-2,3,7,7a-tetrahydro-1H-indole-6-carboxylate
(7aR)-3-(carboxylatomethyl)-6-nitro-7,7a-dihydro-1H-indole-2-carboxylate
(S)-2-amino-5-fluoro-4-oxo-5-phosphono-pentanoic acid
irreversible inhibition
(S)-2-amino-5-phosphono-pent-4-ynoic acid
-
1-amino-2-naphthol-4-sulfonic acid
-
-
-
2,3-dichloro-1,4-naphthoquinone
-
-
2,3-dichloro-5,6-dicyano-1,4-benzoquinone
-
-
2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone
-
-
-
2-bromo-1,4-naphthoquinone
-
-
-
2-Chloro-1,4-naphthoquinone
-
-
2-chloro-3-methoxy-1,4-naphthoquinone
a selective, low to sub-micromolar inhibitors of the fungal ASADHs
-
3-Chloroacetylpyridine-adenine dinucleotide phosphate
-
NADP+ and NADPH protect
3-hydroxyaspartic acid
-
-
4-([[(1S)-1-carboxy-2-hydroxyethyl]amino]methyl)benzene-1,2-dicarboxylic acid
4-([[(1S)-1-carboxyethyl]amino]methyl)benzene-1,2-dicarboxylic acid
4-benzoquinone
enzyme binding structure analysis, a competitive and rel. weak inhibitor. The carbonyl oxygens of the inhibitor each participate in hydrogen bonds, one with the epsilon-nitrogen of Lys211 and the guanidine nitrogen of Arg114 (substrate binding residues), and the other with the thiol of the Cys154 nucleophile. There are also hydrophobic interactions with Asn153. While the position of these carbonyl groups are fixed, the aromatic ring adopts a somewhat different orientation in each of the subunits of the dimer
4-nitro-N,N-diethylbenzimidazolinone
4-nitro-N,N-dimethylbenzimidazolinone
4-nitro-N-ethylphthalimide
4-nitro-N-methylphthalimide
5-(carboxylatocarbonyl)-1H-pyrrole-2-carboxylate
5-aminoisoquinoline
-
-
-
5-[[(4-nitrophenyl)amino]carbonyl]-1,3-benzenedimethylcarboxylate
acetylenic and z-olefinic analogues
-
competitive inhibition
-
adenosine 5'-triphosphate
-
causes a time-dependent inactivation at a concentration of 3.5 mM, 0°C, pH 6.5 and 2 mM dithiothreitol, inactivation can be completely reversed by warming the reaction mixture to 25°C, 50% inactivation occurs at a concentration of 2.5 mM, NADH protects
aromatic aldehydes
-
e.g.: benzaldehyde, weak
caulerpin
-
molecular docking and dynamics simulation of Vibrio anguillarum aspartate semialdehyde dehydrogenase with natural product caulerpin, which binds with high energy. Caulerpin can be used as antibiotic against Vibrio anguillarum in fish aquaculture industry
cis-5-phosphonic acid pipecolic acid
-
-
cysteine
-
in the reverse reaction
D-Cystine
-
70% inhibition at 0.01 mM, binds via the cysteine moiety covalently to the catalytic Cys135 of the enzyme, pH-dependent proces, optimal at pH 7.0-7.5, inhibition is reversible by DTT, dithioerythritol, 2-mercaptoethanol, dimercaptopropanol, and reduced glutathione, no protection by aspartate-beta-semialdehyde, NADP+ or NADPH, inhibition mechanism and kinetics
dimethyl pyridine-2,5-dicarboxylate
DTNB
-
reversible by DTT, dithioerythritol, 2-mercaptoethanol, dimercaptopropanol, and reduced glutathione
GSSG
-
oxidized glutathione
homocysteine
-
in the reverse reaction
iodoacetamide
-
at 0.1 mM: 45.4% inactivation in the absence of NADP+, 22% inactivation in the presence of 1 mM NADP+
L-2-Amino-4-oxo-5-chloropentanoic acid
L-cystine diethyl ester
-
68% inhibition at 0.01 mM, reversible by DTT, dithioerythritol, 2-mercaptoethanol, dimercaptopropanol, and reduced glutathione
L-cystine dimethyl ester
-
67% inhibition at 0.01 mM, reversible by DTT, dithioerythritol, 2-mercaptoethanol, dimercaptopropanol, and reduced glutathione
L-cystine hydroxamate
-
20% inhibition at 0.01 mM, reversible by DTT, dithioerythritol, 2-mercaptoethanol, dimercaptopropanol, and reduced glutathione
L-leucine
-
inhibits, when added to a final concentration of 10 mM in the assay system produces a decrease of 0.004 units in specific activity
methyl 5-nitropyridine-2-carboxylate
N-((4-(2-benzyl)vinyl)benzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(1-naphthyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(2-bromobenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(2-methylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(2-naphthyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(2-trifluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(2-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(3-bromobenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(3-methylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(3-trifluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(3-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-(2-perfluoropropyl))-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-biphenyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-bromobenzyl)-N-(2-carboxy)ethyl-3,4-dicarboxybenzylamine
-
-
N-(4-bromobenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-carboxamidebenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-carboxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-difluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-methylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-t-butylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-trifluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(4-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-(ethylmorpholino)-N-carboxymethyl-3,4-dicarboxybenzylamine
N-acetal-N-carboxymethyl-3,4-dicarboxybenzylamine
N-acetonitrile, N-carboxymethyl-3,4-dicarboxybenzylamine
N-allyl, N-carboxymethyl-3,4-dicarboxybenzylamine
N-benzyl, N-carboxymethyl-3,4-dicarboxybenzylamine
N-carboxyethyl-3,4-dicarboxybenzylamine
N-carboxymethyl-3,4-dicarboxybenzylamine
N-methyl, N-carboxymethyl-3,4-dicarboxybenzylamine
NADPH-Tris-chloride buffer
-
promotes a weak inactivation at 0°C, NADH protects
naphthalene-2,3-dialdehyde
-
-
-
p-hydroxymercuribenzoate
-
-
perrhenate
-
very weak inhibitor
phosphonate
-
weak inhibitor
pipecolic acid-5-(R)-phosphate hydrochloric acid
-
-
pipecolic acid-5-(S)-phosphate hydrochloric acid
-
-
potassium phosphate
-
at a concentration of 10 mM promotes 60% inactivation at 0°C in the presence of 10 mM ATP, at a concentration of 100 mM promotes 61% inactivation in the presence of 10 mM ATP and 32% inactivation in the absence of ATP, NADH protects
S-methyl cysteine sulfoxide
inhibitor binding structure deduced from crystal structure
S-methyl-L-cysteine sulfoxide
covalently binding inhibitor via Cys134 at the active site, inactivation, inhibition and binding mechanism, reversible by addition of DTT or 2-mercaptoethanol
tetrachloro-1,4-benzoquinone
-
-
thieno[2,3-b]thiophene-2,5-dicarboxylate
trans-5-phosphonic acid pipecolic acid
-
-
(1R)-5-[(2-carboxyphenyl)carbamoyl]cyclohexa-3,5-diene-1,3-dicarboxylate
-
-
(1R)-5-[(2-carboxyphenyl)carbamoyl]cyclohexa-3,5-diene-1,3-dicarboxylate
-
(1R)-5-[(3-nitrophenyl)carbamoyl]cyclohexa-3,5-diene-1,3-dicarboxylate
-
-
(1R)-5-[(3-nitrophenyl)carbamoyl]cyclohexa-3,5-diene-1,3-dicarboxylate
-
(1R)-5-[(4-nitrophenyl)carbamoyl]cyclohexa-3,5-diene-1,3-dicarboxylate
-
-
(1R)-5-[(4-nitrophenyl)carbamoyl]cyclohexa-3,5-diene-1,3-dicarboxylate
-
(2R,3aR)-5-[(methylsulfonyl)methyl]-2,3,3a,4-tetrahydro-1H-indole-2-carboxylate
-
-
(2R,3aR)-5-[(methylsulfonyl)methyl]-2,3,3a,4-tetrahydro-1H-indole-2-carboxylate
-
(2R,5R)-2,3,4,5-tetrahydropyridine-2,5-dicarboxylate
-
-
(2R,5R)-2,3,4,5-tetrahydropyridine-2,5-dicarboxylate
-
(2R,5R)-5-nitro-2,3,4,5-tetrahydropyridine-2-carboxylate
-
-
(2R,5R)-5-nitro-2,3,4,5-tetrahydropyridine-2-carboxylate
-
(2R,7aR)-2,3,7,7a-tetrahydro-1H-indole-2,6-dicarboxylate
-
-
(2R,7aR)-2,3,7,7a-tetrahydro-1H-indole-2,6-dicarboxylate
-
(2R,7aR)-6-hydroxy-2,3,7,7a-tetrahydro-1H-indole-2-carboxylate
-
-
(2R,7aR)-6-hydroxy-2,3,7,7a-tetrahydro-1H-indole-2-carboxylate
-
(2R,7aR)-6-nitro-2,3,7,7a-tetrahydro-1H-indole-2-carboxylate
-
-
(2R,7aR)-6-nitro-2,3,7,7a-tetrahydro-1H-indole-2-carboxylate
-
(2R,8aR)-2,7-dinitro-1,2,8,8a-tetrahydronaphthalene
-
-
(2R,8aR)-2,7-dinitro-1,2,8,8a-tetrahydronaphthalene
-
(3aR)-2-oxo-2,3,3a,4-tetrahydro-1H-benzimidazole-5-carboxylic acid
-
-
(3aR)-2-oxo-2,3,3a,4-tetrahydro-1H-benzimidazole-5-carboxylic acid
-
(3aR)-5-nitro-1,3,3a,4-tetrahydro-2H-benzimidazol-2-one
-
-
(3aR)-5-nitro-1,3,3a,4-tetrahydro-2H-benzimidazol-2-one
-
(3aR)-5-nitro-3a,4-dihydro-1H-indene-1,3(2H)-dione
-
-
(3aR)-5-nitro-3a,4-dihydro-1H-indene-1,3(2H)-dione
-
(3aR)-5-nitro-3a,4-dihydro-1H-isoindole-1,3(2H)-dione
-
-
(3aR)-5-nitro-3a,4-dihydro-1H-isoindole-1,3(2H)-dione
-
(3aR)-6-chloro-5-nitro-3a,4-dihydro-1H-isoindole-1,3(2H)-dione
-
-
(3aR)-6-chloro-5-nitro-3a,4-dihydro-1H-isoindole-1,3(2H)-dione
-
(7aR)-2-oxo-2,3,7,7a-tetrahydro-1H-indole-6-carboxylate
-
-
(7aR)-2-oxo-2,3,7,7a-tetrahydro-1H-indole-6-carboxylate
-
(7aR)-3-(carboxylatomethyl)-6-nitro-7,7a-dihydro-1H-indole-2-carboxylate
-
-
(7aR)-3-(carboxylatomethyl)-6-nitro-7,7a-dihydro-1H-indole-2-carboxylate
-
2-Aminoadipate
-
-
4-([[(1S)-1-carboxy-2-hydroxyethyl]amino]methyl)benzene-1,2-dicarboxylic acid
-
-
4-([[(1S)-1-carboxy-2-hydroxyethyl]amino]methyl)benzene-1,2-dicarboxylic acid
-
-
4-([[(1S)-1-carboxyethyl]amino]methyl)benzene-1,2-dicarboxylic acid
-
-
4-([[(1S)-1-carboxyethyl]amino]methyl)benzene-1,2-dicarboxylic acid
-
-
4-nitro-N,N-diethylbenzimidazolinone
-
-
4-nitro-N,N-diethylbenzimidazolinone
-
4-nitro-N,N-dimethylbenzimidazolinone
-
-
4-nitro-N,N-dimethylbenzimidazolinone
-
4-nitro-N-ethylphthalimide
-
-
4-nitro-N-ethylphthalimide
-
4-nitro-N-methylphthalimide
-
-
4-nitro-N-methylphthalimide
-
5-(carboxylatocarbonyl)-1H-pyrrole-2-carboxylate
-
-
5-(carboxylatocarbonyl)-1H-pyrrole-2-carboxylate
-
5-[[(4-nitrophenyl)amino]carbonyl]-1,3-benzenedimethylcarboxylate
-
-
5-[[(4-nitrophenyl)amino]carbonyl]-1,3-benzenedimethylcarboxylate
-
dimethyl pyridine-2,5-dicarboxylate
-
-
dimethyl pyridine-2,5-dicarboxylate
-
iodoacetate
-
-
iodoacetate
-
inhibition of arsenolysis, inhibition of the reduction of beta-aspartyl phosphate
iodoacetate
-
at 1 mM: completely inhibits in the absence or presence of NADP+, at 0.1 mM: 3% inactivation in the absence of NADP+, 50% inactivation in the presence of 1 mM NADP+
L-2-Amino-4-oxo-5-chloropentanoic acid
-
L-aspartate 4-semialdehyde protects the enzyme against inactivation, both NADP+ and NADPH decrease the rate of inactivation
L-2-Amino-4-oxo-5-chloropentanoic acid
-
substrate analogue, irreversible inactivation, pseudo-first-order kinetics
L-cystine
-
complete inhibition at 0.01 mM, binds via the cysteine moiety covalently to the catalytic Cys135 of the enzyme, pH-dependent process, optimal at pH 7.0-7.5, inhibition is reversible by DTT, dithioerythritol, 2-mercaptoethanol, dimercaptopropanol, and reduced glutathione, no protection by aspartate-beta-semialdehyde, NADP+ or NADPH, inhibition mechanism and kinetics
L-cystine
inactivation, reversible by addition of DTT or 2-mercaptoethanol
L-isoleucine
-
at 1 mM: 18% repression of enzyme synthesis, at 5 mM: 62% repression of enzyme synthesis
L-isoleucine
-
inhibits, when added to a final concentration of 10 mM in the assay system produces a decrease of 0.003 units in specific activity
L-lysine
-
at 1 mM: 22% repression of the enzyme synthesis, at 5 mM: 44% repression of the enzyme synthesis, at 10 mM: 28% inhibition of the enzyme activity assayed in the reverse reaction
L-lysine
-
enzyme assayed in the reverse reaction at pH 10
L-lysine
-
slightly represses the enzyme
L-methionine
-
at 1 mM: 40% repression of the enzyme synthesis, at 5 mM: 62% repression of the enzyme synthesis
L-methionine
-
inhibits, when added to a final concentration of 10 mM in the assay system produces a decrease of 0.004 units in specific activity
L-threonine
-
at 1 mM: 25% repression of the enzyme synthesis, at 5 mM: 43% repression of the enzyme synthesis, at 10 mM: 37% inhibition of the enzyme activity assayed in the reverse reaction
L-threonine
-
enzyme assayed in the reverse reaction at pH 10
L-threonine
-
represses the enzyme considerably
methyl 5-nitropyridine-2-carboxylate
-
-
methyl 5-nitropyridine-2-carboxylate
-
N-((4-(2-benzyl)vinyl)benzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-((4-(2-benzyl)vinyl)benzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(1-naphthyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(1-naphthyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-bromobenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-bromobenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-methylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-methylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-naphthyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-naphthyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-trifluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-trifluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(2-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(3-bromobenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(3-bromobenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(3-methylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(3-methylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(3-trifluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(3-trifluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(3-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(3-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-(2-perfluoropropyl))-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-(2-perfluoropropyl))-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-biphenyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-biphenyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-bromobenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-bromobenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-carboxamidebenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-carboxamidebenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-carboxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-carboxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-difluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-difluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-methylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-methylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-t-butylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-t-butylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-trifluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-trifluoromethoxybenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(4-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(ethylmorpholino)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-(ethylmorpholino)-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-acetal-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-acetal-N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-acetonitrile, N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-acetonitrile, N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-allyl, N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-allyl, N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-benzyl, N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-benzyl, N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-carboxyethyl-3,4-dicarboxybenzylamine
-
-
N-carboxyethyl-3,4-dicarboxybenzylamine
-
-
N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-ethylmaleimide
-
-
N-ethylmaleimide
-
only 1 mol per subunit causes complete inactivation, at 0.1 mM: 91% inactivation in the absence of NADP+, 12% inactivation in the presence of 1 mM NADP+
N-methyl, N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
N-methyl, N-carboxymethyl-3,4-dicarboxybenzylamine
-
-
petrosamine B
-
50% inhibition at 0.306 mM. Petrosamine B is a pyridoacridine alkaloid isolated from the sponge Oceanapia sp.; isolated from the methanol extract of the saustralian sponge Oceanapia sp.
petrosamine B
-
50% inhibition at 0.306 mM. Petrosamine B is a pyridoacridine alkaloid isolated from the sponge Oceanapia sp.
thieno[2,3-b]thiophene-2,5-dicarboxylate
-
-
thieno[2,3-b]thiophene-2,5-dicarboxylate
-
Tris salts
-
-
Tris salts
-
100 mM promotes 60.5% inactivation in the presence of 10 mM ATP and 17% inactivation in the absence of ATP
additional information
-
cytotoxicity analysis of inhibitors against Candida albicans cells, overview
-
additional information
-
-
-
additional information
-
not: chelating agents
-
additional information
-
no inhibition by N,N'-diacetyl-L-cystine, L-cystine di-beta-naphthylamide, disulfiram, N-acetyl-L-cystine, 2,2-dithiodipyridine, 4,4-dithiodipyridine, L- and D-cysteine, and oxidized and reduced coenzyme A
-
additional information
inhibitor binding structure and mechanism
-
additional information
molecular docking and simulation studies of the priority target, enzyme ASD, reveals the therapeutic potential of the ASD inhibitors based on selected natural products (huperzine A, rosmarinic acid, and curcumin), overview
-
additional information
-
no feed-back inhibition by threonine or methionine
-
additional information
-
-
-
additional information
-
the ASADH enzyme family shares the same substrate binding and active site catalytic groups, but the enzymes from representative bacterial and fungal species show different inhibition patterns when previously screened against low molecular weight inhibitors identified from fragment library screening. ASADH inhibitor development, overview
-
additional information
no inhibition by pathway endproducts amino acids threonine, methionine, lysine, and isoleucine
-
additional information
-
no inhibition by pathway endproducts amino acids threonine, methionine, lysine, and isoleucine
-
additional information
-
the ASADH enzyme family shares the same substrate binding and active site catalytic groups, but the enzymes from representative bacterial and fungal species show different inhibition patterns when previously screened against low molecular weight inhibitors identified from fragment library screening. ASADH inhibitor development, overview. No inhibition by 4-([[(1S)-1-carboxy-2-hydroxyethyl]amino]methyl)benzene-1,2-dicarboxylic acid, N-(4-bromobenzyl)-N-carboxyethyl-3,4-dicarboxybenzylamine , and N-(4-trifluoromethylbenzyl)-N-carboxymethyl-3,4-dicarboxybenzylamine
-